GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Research & Development

Gala Pharmaceutical (Gala Pharmaceutical) Research & Development : $0.00 Mil (TTM As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Gala Pharmaceutical's Research & Development for the three months ended in May. 2019 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in May. 2019 was $0.00 Mil.

Gala Pharmaceutical Research & Development Historical Data

The historical data trend for Gala Pharmaceutical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Research & Development Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
Research & Development
Get a 7-Day Free Trial - - - - -

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gala Pharmaceutical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in May. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gala Pharmaceutical  (OTCPK:GLPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gala Pharmaceutical Research & Development Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Research & Development
Comparable Companies
LSE:PYC PRTX PPCB BTHE TSXV:IBT XCNQ:DOSE TSXV:APC RSPI XCNQ:LILY OBMP ASX:MEB XSAT:CLINE B AMBS WAR:RDG ASX:ACL TNTY TSXV:MFS VODG GOVX ASX:RAC
Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Website
https://www.galapharmaceuticals.com
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.